Théa and Coave Therapeutics sign an exclusive agreement

Innovation

Coave Therapeutics and Théa Open Innovation sign exclusive licensing, codevelopment and commercialization agreement for Europe for CTx-PDE6b, a novel gene therapy candidate in retinitis pigmentosa